SHIFT Newsroom · GLOBAL
CBL-514: Phase 3 dosing and the limits of weight-regain claims
Catch-up: Phase 3 dosing announced 23 September; separate EASD research release dated 1 October 2026.
Caliway announced on 23 September that the first participant had been dosed in SUPREME-01, a placebo-controlled Phase 3 trial of CBL-514 for reducing local abdominal subcutaneous fat. The announcement does not give the exact dosing day. The trial registry lists recruitment and an actual study start of 1 September; that is a separate milestone. This is body-contouring research, not proof of general obesity treatment.
The sponsor also announced preclinical combination findings on weight regain for a November conference. Those findings do not establish lasting weight loss in humans. SUPREME-01 has no results posted in its registry as checked on 19 October.
A separate EASD release dated 1 October reported human MRI findings from a small Phase 2 subgroup. It distinguishes 41 participants at baseline from 40 with later follow-up. This is preliminary conference evidence with commercial conflicts, not a Phase 3 result or proof of lasting human weight-loss maintenance. The weight-regain combination findings described in that release were in rats.
SHIFT’s take
CBL-514 merits monitoring, but current evidence does not establish UK authorisation, NHS access or permanent human weight-loss benefit.
Known facts
- First participant dosing was announced on 23 September 2026; the exact dosing day was not stated.